Navigation Links
Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
Date:4/14/2008

(PHILADELPHIA) Researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia are inching closer to understanding how common blood pressure medications might help prevent the spread of pancreatic cancer. They have found in the laboratory that one type of pressure-lowering drug called an angiotensin receptor blocker inhibits pancreatic cancer cell growth and causes cell death.

In earlier work in the laboratory, Hwyda Arafat, M.D., Ph.D., associate professor of Surgery at Jefferson Medical College, and her team showed that angiotensin receptor blockers may help reduce the development of tumor-feeding blood vessels, a process called angiogenesis. Other studies have linked a lower incidence of cancer with the use of angiotensin blocking therapies. Such drugs, she says, may become part of a novel strategy to control the growth and spread of cancer.

One of these drugs AT1R (Ang II type 1 receptor) blockers inhibit the function of the hormone angiotensin II (Ang II) in the pancreas. The receptor is expressed in pancreatic cancer cells. Ang II increases the production of VEGF, a vascular factor that promotes blood vessel growth in a number of cancers. High VEGF levels have been correlated with poor cancer prognosis and early recurrence after surgery. Dr. Arafats research team has shown that AngII indirectly causes VEGF expression by increasing AT1R expression.

Dr. Arafats group explored the effects of blocking AT1R on the pancreatic cancer cell reproductive cycle and programmed cell death, or apoptosis, and the mechanisms involved. It found that blocking AT1R inhibited pancreatic cancer cell growth and promoted cell death. This happens through inducing the activity of the gene p53, which controls programmed cell death, and also by inhibiting anti-cell death pathways such as those involving the gene bcl-2. The team reports its findings April 14, 2008 at the annual meeting of the American Association for Cancer Research in San Diego.

The researchers also found that blocking AT1R affects p21, a gene that regulates the cell cycle. We found that blocking this receptor can cause cell cycle arrest, she notes.

This is really exciting because the role of this receptor has never been known, Dr. Arafat says. Its never been connected to cell division or apoptosis. Were also now further exploring the mechanisms involved. The exciting thing is that this receptor already has so many available pharmaceutical blockers on the market. Ultimately, the group hopes to be able to test these agents in human trials, she says.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
2. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
3. Blood vessels: The pied piper for growing nerve cells
4. Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes
5. Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit
6. Microwave treatments for enlarged prostate cause blood pressure surges
7. Blood pressure enzyme can have tumor-sensing role
8. Stem cell research leads to potential new therapy for rare blood disorder
9. Gator Blood May Be New Source of Antibiotics
10. Leaky blood vessels open up nerve cells to toxic assault in Lou Gehrigs disease
11. Tight Backpack Straps Cut Blood to Shoulders, Arms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 20, 2017 , ... EdChoice and the American Enterprise Institute ... promote economic development in economically distressed urban areas. The first report presents a ... to the economic development of the city of Santa Ana, California. The second ...
(Date:6/20/2017)... Ohio (PRWEB) , ... June 20, 2017 , ... ... gum disease in Cincinnati, OH for leading-edge care, whether or not ... in laser dentistry. Using the BIOLASE WaterLase® iPlus™ laser, she targets bacteria and ...
(Date:6/20/2017)... ... June 20, 2017 , ... Many RNA binding proteins ... the research team developed expressRNA, a web platform encompassing computational tools for integration ... nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind to specific positions ...
(Date:6/20/2017)... ... 20, 2017 , ... John D'Eri, CEO of Rising Tide Car Wash ... Award during the Autism Society of America 's 49th annual conference to ... Fiddle Foundation (DJFF) was founded in 2002 as the nation's first autism organization ...
(Date:6/20/2017)... ... June 20, 2017 , ... Bellus Medical, a leader ... Vice President of Sales, a critical role to help spearhead business development, strategic ... , Mr. McKenna is a seasoned business leader, joining Bellus Medical with more ...
Breaking Medicine News(10 mins):
(Date:5/29/2017)... 2017  Cellect Biotechnology Ltd. (NASDAQ: APOP ... the functional selection of stem cells, today provided a ... quarter ended March 31 st , 2017. ... the first quarter of 2017," said Dr. Shai Yarkoni, ... the treatment of the first blood cancer patient in ...
(Date:5/26/2017)... May 25, 2017  In response to the opioid ... Direct Relief is working with Pfizer to make up ... no cost to community health centers, free and charitable ... "Pfizer has a long-standing commitment to ... ensuring patient safety through educational activities," said Caroline ...
(Date:5/23/2017)... May 23, 2017  Leaf Healthcare, recognized for ... devices for pressure ulcer prevention, will unveil its ... of Critical Care Nurses, National Teaching Institute and ... The Leaf Patient Monitoring System is the ... hospital environment.  The system seamlessly tracks patient movement ...
Breaking Medicine Technology: